Get the Stockscreener App
1.23
0.00%
0.00
After Hours:
1.22
-0.01
-0.81%
Pmv Pharmaceuticals Inc stock is traded at $1.23, with a volume of 1.68M.
It is up +0.00% in the last 24 hours and down -13.38% over the past month.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
See More
Previous Close:
$1.23
Open:
$1.22
24h Volume:
1.68M
Relative Volume:
1.78
Market Cap:
$65.18M
Revenue:
-
Net Income/Loss:
$-51.47M
P/E Ratio:
-1.23
EPS:
-1
Net Cash Flow:
$-47.50M
1W Performance:
-15.75%
1M Performance:
-13.38%
6M Performance:
-2.38%
1Y Performance:
-17.45%
1-Day Range:
$1.22
$1.40
1-Week Range:
$1.19
$1.84
52-Week Range:
$0.81
$1.84
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Name
Pmv Pharmaceuticals Inc
Sector
Industry
Phone
(609) 642-6670
Address
400 ALEXANDER PARK DRIVE, PRINCETON
Compare PMVP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
1.23 | 67.30M | 0 | -51.47M | -47.50M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Upgrade | Oppenheimer | Perform → Outperform |
| May-13-24 | Initiated | Craig Hallum | Buy |
| Apr-12-24 | Initiated | Jefferies | Buy |
| Dec-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Mar-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-22-21 | Upgrade | Goldman | Neutral → Buy |
| Aug-19-21 | Initiated | Oppenheimer | Perform |
| Aug-02-21 | Initiated | Guggenheim | Buy |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Cowen | Outperform |
| Oct-20-20 | Initiated | Evercore ISI | Outperform |
| Oct-20-20 | Initiated | Goldman | Neutral |
View All
Pmv Pharmaceuticals Inc Stock (PMVP) Latest News
Will PMV Pharmaceuticals Inc. stock return to pre crisis levels2025 Stock Rankings & Capital Efficiency Focused Ideas - baoquankhu1.vn
Sector ETF performance correlation with PMV Pharmaceuticals Inc.2025 Retail Activity & Weekly High Return Stock Opportunities - Newser
Trend analysis for PMV Pharmaceuticals Inc. this weekMarket Activity Recap & Safe Entry Trade Reports - Newser
Ranking PMV Pharmaceuticals Inc. among high performing stocks via toolsWeekly Market Summary & Free Safe Entry Trade Signal Reports - Newser
Published on: 2025-09-12 12:42:36 - Newser
Developing predictive dashboards with PMV Pharmaceuticals Inc. dataTrend Reversal & Daily Stock Momentum Reports - Newser
Can machine learning forecast PMV Pharmaceuticals Inc. recoveryPortfolio Update Report & Stepwise Entry/Exit Trade Alerts - Newser
Can PMV Pharmaceuticals Inc. hit a new high this monthJuly 2025 Decliners & Fast Gaining Stock Strategy Reports - Newser
Volume spikes in PMV Pharmaceuticals Inc. stock – what they mean2025 Price Targets & Verified Chart Pattern Trade Signals - Newser
Predicting PMV Pharmaceuticals Inc. trend using moving averagesEarnings Recap Summary & Daily Stock Trend Watchlist - Newser
Is PMV Pharmaceuticals Inc. meeting your algorithmic filter criteriaInsider Selling & Verified Swing Trading Watchlist - Newser
Published on: 2025-09-11 23:08:00 - Newser
Is PMV Pharmaceuticals Inc. stock bottoming outMarket Movement Recap & Real-Time Buy Zone Alerts - Newser
What does recent volatility data suggest for PMV Pharmaceuticals Inc.Bull Run & Accurate Trade Setup Notifications - Newser
Visual trend scoring systems applied to PMV Pharmaceuticals Inc.July 2025 Pullbacks & Daily Volume Surge Trade Alerts - Newser
Evaluating PMV Pharmaceuticals Inc. with trendline analysisWeekly Earnings Recap & Weekly Return Optimization Alerts - Newser
How institutional ownership impacts PMV Pharmaceuticals Inc. stockWall Street Watch & Free Daily Entry Point Trade Alerts - Newser
Long term hold vs stop loss in PMV Pharmaceuticals Inc.Options Play & High Win Rate Trade Tips - Newser
Applying big data sentiment scoring on PMV Pharmaceuticals Inc.July 2025 Snapshot & Daily Profit Focused Screening - Newser
Candlestick signals on PMV Pharmaceuticals Inc. stock todayQuarterly Performance Summary & Fast Momentum Entry Tips - Newser
Can technical indicators confirm PMV Pharmaceuticals Inc.’s reversal2025 Price Action Summary & Weekly Stock Performance Updates - Newser
Does PMV Pharmaceuticals Inc. fit your quant trading model2025 Pullback Review & Capital Efficient Trade Techniques - Newser
Reversal indicators forming on PMV Pharmaceuticals Inc. stockDividend Hike & Technical Buy Zone Confirmation - Newser
Can momentum traders help lift PMV Pharmaceuticals Inc.Sell Signal & Real-Time Volume Trigger Notifications - Newser
PMV Pharmaceuticals stock rating reiterated at Buy by TD Cowen - Investing.com
Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types - AOL.com
TD Cowen Maintains PMV Pharmaceuticals(PMVP.US) With Buy Rating - 富途牛牛
For PMV Pharma, Ovarian Cancer Is First Big Stop On Rezatapopt’s Regulatory Journey - insights.citeline.com
Why Is PMV Pharmaceuticals Stock Falling WednesdayPMV Pharma (NASDAQ:PMVP) - Benzinga
Is PMV Pharmaceuticals Ready for a Bounce Back? - timothysykes.com
PMV Pharma Reports Positive Interim Data From Phase 2 PYNNACLE Study - Nasdaq
PMV Pharmaceuticals surges on positive cancer therapy trial data - TradingView
PMV Pharmaceuticals stock soars after promising cancer drug trial results By Investing.com - Investing.com Canada
PMV Pharma reports 33% response rate in TP53 Y220C mutation trial - Investing.com Nigeria
PMV Pharma Announces Promising Interim Data from PYNNACLE Phase 2 Trial of Rezatapopt in Multiple Tumor Types - Quiver Quantitative
PMV Pharmaceuticals Announces Promising Rezatapopt - GlobeNewswire
33% Response Rate Across 8 Cancer Types: PMV Pharma's Breakthrough TP53 Drug Shows Promise in Phase 2 Trial - Stock Titan
What the charts say about PMV Pharmaceuticals Inc. todayMarket Risk Analysis & Weekly Watchlist of Top Performers - Newser
What to do if you’re stuck in PMV Pharmaceuticals Inc.Entry Point & Free AI Powered Buy and Sell Recommendations - Newser
How to escape a deep drawdown in PMV Pharmaceuticals Inc.July 2025 Snapshot & Daily Entry Point Alerts - Newser
How much upside does SXTPW haveProfit Target & High Return Trade Opportunity Guides - Lancaster City Council
What is the implied volatility of AlphaTime Acquisition Corp2025 Short Interest & Real-Time Price Movement Reports - Lancaster City Council
What’s the outlook for PMV Pharmaceuticals Inc.’s sectorWeekly Investment Report & Long Hold Capital Preservation Tips - Lancaster City Council
Pmv Pharmaceuticals Inc Stock (PMVP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):